Who Owns Padcev?
Padcev is owned by Pfizer Inc. (NYSE: PFE) in partnership with Astellas Pharma. Pfizer acquired rights through its December 2023 acquisition of Seagen for approximately $43 billion. Padcev (enfortumab vedotin) is an antibody-drug conjugate first FDA approved in December 2019 for urothelial bladder cancer and is co-commercialized with Astellas.
Padcev Timeline
GlobalOfficial Website
Who Owns Padcev?
- Parent Company: Pfizer Inc.
- Ownership Type: Subsidiary
- Acquisition Year: 2023
- Company Type: Publicly Traded
- Stock Ticker: NYSE: PFE
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Padcev | Pfizer Inc. | Subsidiary |
Where to Buy
Disclosure: We may earn commission from purchases
Padcev on AmazonAdvertisement
History of Padcev
- Founded: 2019
- Founders: Seagen Inc. (original development), Astellas Pharma (co-developer)
- Acquired by Pfizer Inc.: 2023
Enfortumab vedotin was developed by Seattle Genetics using its proprietary antibody-drug conjugate technology: a monoclonal antibody targeting Nectin-4, a protein highly expressed on urothelial cancer cells, linked to the cytotoxic payload monomethyl auristatin E. The design delivers the toxic payload directly into cancer cells that express the target.
Astellas joined as partner during development, sharing costs and gaining co-commercialization rights. The FDA granted accelerated approval on December 18, 2019, for patients with locally advanced or metastatic urothelial cancer who had received prior platinum chemotherapy and immunotherapy, a population with few remaining options.
Regular approval followed in July 2021 after confirmatory trials. The transformative moment came with the combination of Padcev plus pembrolizumab (Keytruda), which demonstrated dramatic survival improvements over chemotherapy in first-line metastatic disease. The FDA approved the combination in December 2023 for first-line use, effectively repositioning Padcev from a salvage therapy into the backbone of frontline bladder cancer treatment.
That data arrived the same month Pfizer closed its $43 billion Seagen acquisition, validating the deal's central thesis: antibody-drug conjugates as a platform technology with major oncology franchises. Padcev revenue accelerated rapidly on the frontline expansion and crossed the billion-dollar annual threshold, becoming one of the fastest-growing products in Pfizer's oncology book through FY2025.
Advertisement
About Pfizer Inc.
What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.
Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.
Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.
Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.
Advertisement
How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.
Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.
What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.
- Founded: 1849
- Headquarters: New York, New York, USA
- Company Type: Publicly Traded
- Stock: NYSE: PFE
- Revenue: $62.6 billion (FY2025)
- Employees: approximately 88,000
Where Is Padcev Made / Based?
- Headquarters: Bothell, Washington, USA
- Manufacturing / Operations: United States, Japan
Padcev Categories & Tags
Padcev Recalls & Controversies
Padcev carries a boxed warning for severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, serious and sometimes fatal events that occurred in a small percentage of trial patients. The label requires close skin monitoring and dose interruption criteria, a toxicity profile oncologists weigh against its survival benefit.
Advertisement
Peripheral neuropathy and hyperglycemia are the other significant labeled toxicities, managed through monitoring and dose adjustment. Post-marketing surveillance continues under the FDA's standard requirements for oncology products.
No market withdrawal or recall has occurred. The drug's pricing, in the tens of thousands of dollars per treatment course, is subject to the same oncology cost scrutiny applied across the category, compounded now by its use in combination with pembrolizumab, which adds the cost of a second high-priced therapy.
Brands Owned by Pfizer Inc.
Healthcare PharmaceuticalsAbrysvo
Owned by Pfizer Inc.
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
rsv-vaccinevaccinesmaternal-immunization
Healthcare PharmaceuticalsAdcetris
Owned by Pfizer Inc.
Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.
oncologyantibody-drug-conjugatelymphoma
Healthcare PharmaceuticalsCaduet
Owned by Pfizer Inc.
Prescription combination drug containing amlodipine and atorvastatin, co-promoted by Pfizer and developed for simultaneous blood pressure and cholesterol management.
prescription-drugcardiovascularhypertension
Healthcare PharmaceuticalsChantix
Owned by Pfizer Inc.
Prescription smoking cessation medication (varenicline) developed by Pfizer, FDA-approved in 2006.
smoking-cessationvareniclinenicotinic-receptor
Healthcare PharmaceuticalsComirnaty
Owned by Pfizer Inc.
Pfizer-BioNTech COVID-19 mRNA vaccine, the first FDA-approved COVID vaccine in the United States, co-commercialized globally by Pfizer and BioNTech.
covid-19mrna-vaccinevaccines
Healthcare PharmaceuticalsDiflucan
Owned by Pfizer Inc.
Prescription antifungal medication (fluconazole) for treating candidiasis, cryptococcal meningitis, and other fungal infections. Developed by Pfizer, FDA-approved in 1990.
antifungalfungal-infectioncandidiasis
Advertisement
Padcev Ownership: Pros & Cons
Advantages
- +Frontline combination with pembrolizumab made Padcev standard of care in metastatic bladder cancer
- +Seagen acquisition gave Pfizer the leading commercial ADC platform
- +Revenue trajectory has been steep since frontline approval, crossing the blockbuster threshold
- +Pfizer's global infrastructure accelerates market access beyond Seagen's standalone reach
Considerations
- -Profit sharing with Astellas limits Pfizer's retention of collaboration-territory revenue
- -Boxed warning for severe skin toxicity requires active management and deters some prescribing
- -ADC competition is intensifying as multiple companies field programs in urothelial cancer
- -Manufacturing complexity of ADCs limits supply-chain flexibility
Frequently Asked Questions About Padcev
Advertisement
Sources & Further Reading
Competitors to Padcev
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Pfizer | United States | 2011 | Mass market | North america | All Genders | |
| Bristol Myers Squibb | USA | 2014 | Mass market | Global | All Genders | |
| Pfizer | USA | 2015 | Mass market | Global | All Genders | |
| Pfizer | USA | 2020 | Mass market | Global | All Genders | |
| Pfizer | USA | 2012 | Mass market | Global | All Genders | |
| Novartis | Switzerland | 2009 | Mass market | North america | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsAdcetris
Owned by Pfizer Inc.
Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.
oncologyantibody-drug-conjugatelymphoma
Healthcare PharmaceuticalsOpdivo
Owned by Bristol Myers Squibb Company
Opdivo (nivolumab) is Bristol Myers Squibb's flagship cancer immunotherapy, an anti-PD-1 antibody approved across more than a dozen tumor types.
prescription-drugoncologyimmunotherapy
Healthcare PharmaceuticalsIbrance
Owned by Pfizer Inc.
Pfizer's CDK4/6 inhibitor (palbociclib) for HR-positive, HER2-negative metastatic breast cancer, one of the company's largest oncology products since its 2015 approval.
oncologybreast-cancercdk46-inhibitor
Healthcare PharmaceuticalsTukysa
Owned by Pfizer Inc.
Oral HER2 inhibitor (tucatinib) for HER2-positive breast cancer including brain metastases, acquired by Pfizer through the 2023 Seagen acquisition.
oncologybreast-cancerher2
Healthcare PharmaceuticalsXtandi
Owned by Pfizer Inc.
Prostate cancer treatment (enzalutamide) co-commercialized by Pfizer and Astellas Pharma, acquired into Pfizer's portfolio through the 2016 Medivation acquisition.
oncologyprostate-cancerandrogen-inhibitor
Healthcare PharmaceuticalsAfinitor
Owned by Novartis
Prescription oncology medicine (everolimus) used to treat certain cancers and tuberous sclerosis complex, developed and marketed by Novartis AG.
oncologycancerpharmaceutical
Competitive Analysis
Market Positioning: Padcev competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Padcev
Looking for brands with different ownership structures? These similar brands are not owned by Pfizer Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Padcev which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Padcev which is under a publicly traded parent company.
Healthcare PharmaceuticalsBenadryl
Owned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
antihistamineallergy-reliefcold-medicine
Privately Owned
Benadryl is privately owned, unlike Padcev which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike Padcev which is under a publicly traded parent company.
Healthcare PharmaceuticalsDuane Reade
Owned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
pharmacydrugstorenew-york
Privately Owned
Duane Reade is privately owned, unlike Padcev which is under a publicly traded parent company.
Healthcare PharmaceuticalsMD Clarity
Owned by MD Clarity
Seattle healthcare SaaS platform for patient cost estimates, payer contract management, and underpayment detection.
healthcare-technologyrevenue-cyclecontract-management
Privately Owned
MD Clarity is privately owned, unlike Padcev which is under a publicly traded parent company.
Pfizer Inc. Stock Information
Advertisement
Jobs at Pfizer Inc.
Latest News About Padcev
Advertisement
Related Articles About Padcev
View more articles
Industry Analysis
Brands That Relocated Headquarters for Tax Reasons
From Pfizer's failed Irish inversion to ExxonMobil's Texas move, discover why brands relocate their headquarters for tax and legal reasons — and how it affects their brand portfolios. Explore our database.
Who Brands StaffMay 22, 2026
TaxHeadquartersCorporate Relocation
Industry Analysis
How Government Policy Shapes Brand Ownership
From antitrust rulings to tariff wars, government policy determines which brands get acquired, which get blocked, and which stay independent. Our guide explains how policy shapes brand ownership. Explore our database.
Who Brands StaffMay 17, 2026
GovernmentPolicyAntitrust
Brand Comparisons
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
Who Brands StaffMar 16, 2026
PharmaceuticalPfizerJohnson And Johnson
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Brandspecialty-pharmacy
Accredo
Specialty pharmacy founded in 1996 in Memphis, serving patients with complex and rare conditions as the specialty pharmacy of Evernorth within The Cigna Group.
Brand in Healthcare & Pharmaceuticals
rare-diseaseevernorth